CRIS Current Research Information System

MARCHESINI REGGIANI, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.856
EU - Europa 13.770
AS - Asia 13.370
SA - Sud America 992
AF - Africa 846
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 5
Totale 48.859
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.701
SG - Singapore 4.060
GB - Regno Unito 3.805
CN - Cina 3.474
VN - Vietnam 2.977
IT - Italia 2.630
DE - Germania 1.864
SE - Svezia 1.161
HK - Hong Kong 1.066
UA - Ucraina 993
IN - India 835
RU - Federazione Russa 823
BR - Brasile 751
FR - Francia 680
IE - Irlanda 534
ZA - Sudafrica 292
NL - Olanda 286
EE - Estonia 274
KR - Corea 218
JP - Giappone 212
BG - Bulgaria 150
CI - Costa d'Avorio 144
FI - Finlandia 134
TG - Togo 130
SC - Seychelles 124
AR - Argentina 99
ID - Indonesia 86
NG - Nigeria 83
CA - Canada 81
JO - Giordania 77
BE - Belgio 74
CH - Svizzera 66
AT - Austria 57
TR - Turchia 50
EC - Ecuador 48
ES - Italia 48
MX - Messico 46
PL - Polonia 46
BD - Bangladesh 41
IR - Iran 37
GR - Grecia 30
IQ - Iraq 28
CL - Cile 27
EG - Egitto 26
MY - Malesia 25
CZ - Repubblica Ceca 24
RO - Romania 24
UZ - Uzbekistan 24
PH - Filippine 23
PK - Pakistan 22
PY - Paraguay 19
LB - Libano 18
AU - Australia 17
CO - Colombia 16
PE - Perù 14
IL - Israele 13
LT - Lituania 12
KZ - Kazakistan 10
TH - Thailandia 10
UY - Uruguay 10
DK - Danimarca 9
DO - Repubblica Dominicana 9
KE - Kenya 9
NP - Nepal 9
SY - Repubblica araba siriana 9
HR - Croazia 8
MA - Marocco 8
MD - Moldavia 8
AE - Emirati Arabi Uniti 7
TW - Taiwan 7
DZ - Algeria 6
HN - Honduras 6
HU - Ungheria 6
LK - Sri Lanka 6
PT - Portogallo 6
SA - Arabia Saudita 6
VE - Venezuela 6
AO - Angola 5
AZ - Azerbaigian 5
OM - Oman 5
SI - Slovenia 5
TN - Tunisia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
MU - Mauritius 4
NO - Norvegia 4
PA - Panama 4
AL - Albania 3
BH - Bahrain 3
BO - Bolivia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SN - Senegal 2
SV - El Salvador 2
ZM - Zambia 2
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
Totale 48.840
Salva come PNG Salva come JPEG
Città #
Southend 3.341
Singapore 2.602
Fairfield 2.590
Ashburn 1.965
Woodbridge 1.268
Seattle 1.162
Wilmington 1.106
Santa Clara 1.089
Hong Kong 1.055
Chandler 1.051
Houston 1.044
Cambridge 908
Princeton 795
Dong Ket 678
Ann Arbor 676
Jacksonville 663
Ho Chi Minh City 606
Hefei 553
Hanoi 525
Dublin 487
Boardman 474
Beijing 459
Westminster 334
Bologna 325
Nanjing 314
Padova 304
Berlin 274
Los Angeles 221
Tokyo 204
Seoul 201
Buffalo 189
Turin 162
Saint Petersburg 161
Milan 157
Dallas 155
San Diego 155
Sofia 147
Jinan 145
Shenyang 145
Abidjan 144
Rome 141
New York 140
Lomé 130
Mülheim 120
Redondo Beach 115
Helsinki 110
Hebei 97
Nanchang 93
Redmond 83
Abeokuta 82
Changsha 82
Frankfurt am Main 81
Medford 80
Tianjin 79
Amman 77
São Paulo 77
Falls Church 74
Brussels 70
Des Moines 70
Mahé 70
Verona 69
Guangzhou 64
Shanghai 64
Haiphong 60
Zhengzhou 59
Yubileyny 57
London 54
Chicago 53
Bengaluru 51
Dearborn 50
Ha Long 49
Da Nang 48
Jiaxing 47
Norwalk 47
Redwood City 46
Munich 45
Ningbo 45
Hangzhou 44
Bremen 42
Falkenstein 42
Olalla 41
Jakarta 40
Phoenix 39
Biên Hòa 38
Nuremberg 38
Parma 37
Bern 34
Hải Dương 34
Haikou 33
Quận Bình Thạnh 33
Florence 32
Bühl 31
Naples 31
The Dalles 31
Kunming 30
Menlo Park 30
Montreal 30
Taizhou 30
Ninh Bình 29
Bari 28
Totale 32.410
Salva come PNG Salva come JPEG
Nome #
Il diabete con epatopatia 738
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 532
Quanto mangio veramente? 492
Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. 454
Prevalenza delle disfunzioni sessuali femminili nelle donne in menopausa con sindrome metabolica. 339
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 295
Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. An overview 252
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial 246
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease 243
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage 241
Does the liver accelerate ageing: Talking muscles and liver? 240
Prevalence of Sexual Dysfunction among Postmenopausal Women with and without Metabolic Syndrome. 223
NAFLD e cirrosi epatica 219
A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity 217
Acute heart failure in the emergency department: a follow-up study 214
The Role of Medications for the Management of Patients with NAFLD 211
Effects of cognitive-behavioral therapy on eating disorders: neurotransmitter secretory response to treatment 209
Predicting Frailty Condition in Elderly Using Multidimensional Socioclinical Databases 209
A randomized controlled trial of metformin vs. vitamin E or prescriptive diet in non-alcoholic fatty liver disease 207
Double-heterozygous mutations involving both HNF1A (MODY3) and HNF4A (MODY1) genes: a case report 206
Cognitive-behavioral strategies to increase the adherence to exercise in the management of obesity 200
A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department 199
Nonalcoholic fatty liver and insulin resistance: a cause-effect relationship? 199
Non-alcoholic steatohepatitis in patients cared in metabolic units 198
Biomechanical and functional alterations in the diabetic foot: Differences between type I and type II Diabetes 197
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. 196
Approcci nutrizionali nella steatoepatite non alcolica 194
A controlled, class-based multicomponent intervention to promote healthy lifestyle and to reduce the burden of childhood obesity 192
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 192
Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease 190
Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis (NAFLD/NASH): treatment 188
Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy 188
The metabolic syndrome in treatment-seeking obese persons 187
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 187
Weight cycling in treatment-seeking obese persons. Data from the QUOVADIS study 185
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 185
Psychological status and depression in patients with liver cirrhosis 184
A physical activity program to reinforce weight maintenance following a bheavior program in overweight/obese subjects. 184
Comparison of WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes 181
Are behavioral approaches feasible and effective in type 2 diabetes? A propensity score analysis 180
Reply to: “Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients” 179
Emotional intelligence, emotion regulation and affectivity in adults seeking treatment for obesity. 178
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 175
An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers 175
The construct validity of the Short Form-36 health survey and its relationship with BMI in obese outpatients 173
Psychological distress in morbid obesity in relation to weight history 173
A position statement on NAFLD/NASH based on the EASL 2009 special conference 173
A randomized trial of energy-restricted high-protein versus high-carbohydrate, low-fat diet in morbid obesity. 173
Weight loss expectations in obese patients seeking treatment at medical centers 171
Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients 171
Pathogenetic mechanisms and cardiovascular risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance 169
Supervised vs. self-selected physical activity for individuals with diabetes and obesity: the Lifestyle Gym program 169
Weight loss for a healthy liver 167
Long-term weight loss maintenance for obesity: A multidisciplinary approach 167
Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential 167
Prospective validation of a proposal for diagnosis and management of patients attending the emergency department for mild head injury 164
Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women 164
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting 163
Behavioral aspects of nonalcoholic fatty liver disease: diet, causes, and treatment 162
Psychological profile and quality of life of morbid obese patients attending a cognitive behavioural program 160
Effects of cognitive-behavioral treatment for weight loss in the family members 160
Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study 159
Cognitive-behavioral treatment of nonalcoholic fatty liver disease: a propensity score-adjusted observational study 159
Update on nutritional supplementation with branched-chain amino acids 157
Progetto "GULLIVER". Intervento nutrizionale via internet nella sindrome metabolica 157
A psychological support program for individuals with type 1 diabetes 157
Eating behavior affects quality of life in type 2 diabetes mellitus 156
AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. 156
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? 154
Venesection for nonalcoholic fatty liver disease unresponsive to lifestyle counselling - a propensity score-adjusted observational study 153
The association between emotional intelligence and weight loss after a psychoeducational intervention for obese patients. 153
Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study 153
Coagulopathy and NICE recommendations for patients with mild head injury 152
Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study 152
3D bone architecture in weight-bearing combined to pressure measurements in the diabetic foot 152
Trattamento dell’obesità: La lezione della storia 151
Which treatment for nonalcoholic fatty liver disease? 151
Compulsive exercise to control shape or weight in eating disorders: Prevalence, associated features and treatment outcome 151
A 360-degree overview of body composition in healthy people: Relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry 150
The management of severe hypoglycemia by the emergency system: The HYPOTHESIS study 150
Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver 149
Treatment of nonalcoholic fatty liver with focus on emerging drugs 149
Lifestyle changes for the treatment of nonalcoholic fatty liver disease-a 2015-19 update 149
Long-term follow-up of web-based and group-based behavioural intervention in NAFLD in a real world clinical setting 148
Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus 148
The effect of lifestyle changes in non-alcoholic fatty liver disease 148
Anthropometry and nutritional rehabilitation in underweight eating disorders 148
Composizione corporea: studio di normalità 147
Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes 147
Continuous care in the treatment of obesity. An observational multicenter study 146
Metabolic Syndrome and NASH 146
Risk of malnutrition (over and under-nutrition): Validation of the JaNuS screening tool 146
Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs 145
ICD code retrieval: Novel approach for assisted disease classification 145
Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach 145
Sense of coherence, self-esteem, and health locus of control in subjects with type 1 diabetes mellitus with/without satisfactory metabolic control 145
Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery 145
Insulin resistance in nonalcoholic fatty liver disease 144
Clinical and psychological correlates of health-related quality of life in obese patients 144
DXA-assessed changes in body composition in obese women following two different weight loss programs 144
Totale 19.197
Salva come PNG Salva come JPEG
Categoria #
all - tutte 140.408
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.408
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.201 0 0 0 0 0 427 172 292 425 333 282 1.270
2021/20226.150 612 229 456 457 679 371 171 470 242 263 1.150 1.050
2022/20235.985 685 818 315 736 420 394 253 330 1.010 178 531 315
2023/20242.040 133 318 117 148 159 360 136 194 82 161 129 103
2024/20257.476 321 1.148 597 583 1.578 394 465 210 114 358 186 1.522
2025/20269.240 1.873 1.653 1.581 1.395 1.858 880 0 0 0 0 0 0
Totale 49.595